HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer

Area of Science:

• Oncology
• Cancer Immunology
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality.
• Immunotherapy, particularly immune checkpoint blockade, shows promise but is less effective in non-immunogenic cancers like PDAC.
• Programmed death ligand 1 (PD-L1) expression is crucial for checkpoint immunotherapy efficacy.

Purpose of the Study:

• To investigate the role of histone deacetylase 3 (HDAC3) in regulating PD-L1 expression in pancreatic cancer.
• To explore the potential of HDAC3 inhibitors as a strategy to enhance pancreatic cancer immunotherapy.

Main Methods:

• Assessed the effect of a specific HDAC3 inhibitor on PD-L1 protein and mRNA levels in pancreatic cancer cells.
• Correlated HDAC3 expression with PD-L1 levels in PDAC patient samples.
• Investigated the involvement of the HDAC3/signal transducer and activator of transcription 3 (STAT3) pathway in PD-L1 transcriptional regulation.

Main Results:

• Specific HDAC3 inhibition decreased PD-L1 protein and mRNA levels in pancreatic cancer cells.
• HDAC3 expression positively correlated with PD-L1 levels in PDAC patient specimens.
• The HDAC3/STAT3 pathway was identified as a key regulator of PD-L1 transcription.

Conclusions:

• HDAC3 plays a critical role in regulating PD-L1 expression in pancreatic cancer.
• HDAC3 inhibition represents a potential therapeutic strategy to improve immunotherapy outcomes for PDAC.
• Understanding the HDAC3/STAT3 pathway offers insights into cancer immunity and PD-L1 regulation.